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ABSTRACT  
The organic cation transporters OCT and OCTN have been reported to play a significant role 
in the cellular uptake of substrates within in vitro lung cells. However, no studies to date have 
investigated the effect of these transporters upon transepithelial absorption of substrates into 
the pulmonary circulation. We investigated the contribution of OCT and OCTN transporters 
to total pulmonary absorption of L-carnitine and the anti-muscarinic drug, ipratropium, across 
an intact isolated perfused rat lung (IPRL).  The results obtained from the IPRL were 
contrasted with active transport in vitro using three human pulmonary cell lines and primary 
rat alveolar epithelial cells. Ex-vivo studies showed that OCT/OCTN transporters do not play 
a role in the overall pulmonary absorption of L-carnitine or ipratropium, as evidenced by the 
effect of chemical inhibition of these transporters upon pulmonary absorption. In contrast, in-
vitro studies showed that OCT/OCTN transporters play a significant role in cellular 
accumulation of substrates with preferential uptake of ipratropium by OCTs, and of L-
carnitine uptake by OCTNs. The results show that in-vitro uptake studies cannot be predictive 
of airway to blood absorption in-vivo. Nevertheless, localised submucosal pulmonary 
concentrations of inhaled drugs and their pulmonary pharmacodynamic profiles may be 
influenced by OCT/OCTN transport activity. 
 
 
 3 
1. Introduction 1 
A number of drug candidates for inhaled therapy are cationic and are therefore potential 2 
substrates for the SLC22 superfamily of ATP-independent polyspecific cation transporters at 3 
the plasma membrane [1]. These transporters include the bidirectional organic cation 4 
transporters OCT 1 (SLC22A1), OCT2 (SLC22A2), OCT3 (SLC22A3) and the sodium-5 
dependent carnitine/cation transporter proteins OCTN1 (SLC22A4) and OCTN2 (SLC22A5).  6 
The majority of inhaled drugs must cross the rate-limiting pulmonary epithelial barrier to 7 
access their pharmacological targets [2], e.g. smooth muscle cells. As such the interaction of 8 
cationic drugs with transporter pathways expressed in pulmonary epithelium may be 9 
important for drug access to underlying pharmacological targets. Indeed this has been the 10 
premise of research by a number of groups (reviewed in [3-5]) exploring the expression of 11 
OCTs/OCTNs within lung epithelium.  12 
The localisation of OCT/OCTN transporters within intact lung has been reported using 13 
protein immunohistochemistry in both humans [6-9] and rodents [6, 8, 10, 11]. Evidence for 14 
expression of OCT and OCTN family members in intact human and rat lung tissue also exists 15 
at the mRNA level [6, 8, 11-13]. Nakanishi et al. [14] showed OCT/OCTN driven 16 
accumulation of ipratropium in lung epithelial tissue, namely tracheal epithelium, following 17 
drug deposition in the tracheal lumen of the mouse.  A number of in vitro cell culture studies 18 
have reported substrate uptake via OCTs and OCTNs in lung epithelial cells including the 19 
active uptake of the model OCT/OCTN cationic substrate (4-(4-dimethylaminostyryl)-N-20 
methylpyridinium; ASP
+
) in normal human bronchial cells [7] and in a range of human 21 
bronchial epithelial cell lines [15-17]. The inhaled anti-muscarinic drug ipratropium has been 22 
implicated as a substrate of both OCTN and OCT transporters depending upon the in vitro 23 
model adopted [18, 19].  One report exists of the facilitative role of organic cation 24 
 4 
transporters upon the absorptive and secretory transport of ASP
+
 across a cell monolayer [15] 25 
with the results showing modest effects upon the overall absorptive transport, despite a 26 
significant extent of cellular uptake.  27 
Here we hypothesized that in a fully intact lung the OCT/OCTN transporters play little or no 28 
role in the transepithelial transport of substrates into the pulmonary vasculature.  To test the 29 
hypothesis we examined in an intact perfused rat lung (IPRL) the role of OCT/OCTN 30 
transport in pulmonary transepithelial permeability of the zwitterionic substrate, L-carnitine, 31 
and the inhaled therapeutic cationic drug, ipratropium; archetype substrates for the pathways 32 
under study. We found the overall solute transport into the IPRL vasculature was 33 
predominantly driven by non-competitive passive processes that eclipse the net effect of any 34 
OCT/OCTN-mediated transport.    35 
2. Materials and Methods 36 
2.1 Materials 37 
 [
3
H]-ipratropium bromide (70 Ci/mmol) was provided by GlaxoSmithKline (Ware, UK) and 38 
[
3
H]-L-carnitine hydrochloride (70 Ci/mmol) was from American Radiochemicals Inc. (St. 39 
Louis, MO). Unlabelled ipratropium, L-carnitine, tetraethylammonium bromide (TEA) and 1-40 
methyl-4-phenylpyridinium iodide (MPP
+
) were purchased from Sigma-Aldrich (Poole, UK). 41 
Cell culture media and supplements were from Invitrogen (Paisley, UK) with cell culture 42 
plastics from Corning Costar (Hemel Hempstead, UK). All other reagents and solvents were 43 
from Fisher Scientific (Loughborough, UK) or Sigma-Aldrich. PCR primers were designed in 44 
house and supplied by Invitrogen (Paisley, UK).  45 
 46 
2.2 Methods 47 
2.2.1 IPRL 48 
 5 
All animal experiments adhered to the UK Animal (Scientific Procedures) Act 1986. Rats 49 
used for all the experiments in this report weighed 250-350g. Animals were normally housed 50 
with a 12 hour day/night cycle and fed ad libitum until the time of surgery.  51 
To examine the transport of ipratropium and L-carnitine across an intact pulmonary barrier an 52 
IPRL preparation was employed as previously described [20, 21]. This model includes an 53 
intra-tracheal airway dosing technique that utilises a pressurized metered dose inhaler 54 
(pMDI) reproducibly delivering a high extent (>95%) of deposited solute liquid aerosol dose 55 
into the lung periphery [22].  Using the pMDI methodology the IPRL was dosed with either 56 
vehicle control (100 µL saline) or a competitive inhibitor (in 100 µL saline), i.e. either 57 
unlabeled solute (125 nmol unlabeled L-carnitine or ipratropium) or the selective OCT 58 
inhibitor (MPP
+
). Twenty minutes later the lungs were similarly dosed with the radiolabeled 59 
substrate (3 µCi of [
3
H]-L-carnitine or [
3
H]-ipratropium in 100µL saline). At discrete 60 
timepoints after lung dosing. 200µL samples were collected from the circulating perfusate 61 
and transferred to scintillation vials for radiochemical analysis.  62 
 63 
2.2.2 Mathematical Modelling 64 
Pulmonary pharmacokinetic absorption parameters were calculated by fitting Equation 1 to 65 
the individual airway to perfusate absorption data using nonlinear regression analysis 66 
(Micromath Scientist 3.0, Missouri, USA).  67 
 68 
      ???????????????????????????????? ? ????? ? ?? ? ?? ? ??????                   Equation 1 69 
 70 
Where, f  represents the available fraction to be transported, k is the absorption rate constant 71 
(min
-1
) and t is time in minutes.   Modelling of the absorption data was not improved by the 72 
 6 
use of more complex models and Equation 1 was deemed the minimum satisfactory model to 73 
provide precise parameter estimates for k and f.     74 
 75 
2.2.3 In-vitro uptake studies 76 
The in vitro active accumulation of substrates of either OCT and/or OCTN transporters, was 77 
studied in a range of continuous lung epithelial cell lines and primary cultures of rat lung 78 
epithelium. The human pulmonary adenocarcinoma cell line, A549 [23], and the human 79 
bronchial epithelial cell line, BEAS-2B, were obtained from ATCC (American Type Culture 80 
Collection; Manassas, VA). 16HBE14o
-
 cells, generated by transformation of normal 81 
bronchial epithelial cells, were from Dr D. C. Gruenert (University of California San 82 
Francisco, San Francisco). Culture of these cells was performed as previously described [24], 83 
and isolation and primary culture of rat alveolar cells to a type I pneumocyte-like phenotype 84 
was undertaken as detailed in previous work [25]. 85 
Solute uptake studies described hereafter were conducted at incubation temperatures of both 86 
37 ºC and 4 
º
C.   Radiolabelled solute was added to each well (24-well format) containing 87 
confluent cell monolayers. The dosings were 1 µCi (15 pmol) [
3
H]-ipratropium or 1 µCi (15 88 
pmol) [
3
H]-L-carnitine giving a final radiolabel probe concentration in each well of 50 nM 89 
(300 mL volume per well).  Time- and temperature-dependent solute uptake was quantified at 90 
discrete timepoints over a 60 min incubation.  91 
Radiolabelled solute uptake studies were also undertaken in the presence of unlabelled 92 
OCT/OCTN competitive inhibitors applied to the cells for a 30 min pre-incubation period 93 
prior to addition of the radiolabel probes.  The unlabelled inhibitors were used to achieve 94 
concentrations of 500µM ipratropium, 100µM L-carnitine, 500µM MPP
+
, 5mM TEA; a no-95 
treatment control comprised radiolabeled solute alone in serum-free DMEM.  Following the 96 
 7 
pre-incubation period, either [
3
H]-ipratropium or [
3
H]-L-carnitine was added to each well and 97 
the uptake of radiolabel allowed to proceed over a 60 min incubation period.   The solute 98 
uptake experiments were terminated by two washes of the cell monolayers with ice-cold PBS 99 
followed by the addition of ice-cold trypsin-EDTA for 5 min, after which the cells were 100 
harvested and suspended in ice-cold DMEM and centrifuged (4 °C, 200 g) for 10 min after 101 
which the supernatant was discarded and the cell pellet collected. This cell washing 102 
procedure was performed three times in total. The resulting cell pellets were transferred to 103 
scintillation vials and mixed with 3mL of BioSafe 3 scintillation fluid and the cell-associated 104 
radioactivity quantified by liquid scintillation counting.   The sodium-dependent nature of 105 
solute uptake for both [
3
H]-ipratropium and [
3
H]-L-carnitine was similarly conducted but 106 
using an incubation buffer where Na
+
 was isotonically replaced with N-methyl-glucamine as 107 
previously described [7].  108 
 109 
2.2.4 Real-time Quantitative Polymerase Chain Reaction (qPCR) 110 
Human OCT (SLC22A1, SLC22A3, SLC22A3), human OCTN (SLC22A4, SLC22A5), rat 111 
OCT (Slc22a1, Slc22a2, Slc22a3) and rat OCTN (Slc22a4, Slc22a5) mRNA sequences were 112 
aligned using BLAST2  and  the NCBI nucleotide gene search used to identify single exon 113 
regions; Oligocalc was used to validate all used transcription variants.  Table 1 shows the 114 
primer sequences used in qPCR experiments.  Total RNA was isolated (RNeasy, Qiagen, 115 
UK) from pulmonary epithelial cells (A549, BEAS-2B, 16HBE14o
-
 or primary rat alveolar 116 
epithelial cells) grown under the same conditions as used in the solute uptake experiments.  117 
Total RNA was also isolated from whole rat lung and liver tissue, with the liver serving as a 118 
positive control that is known to express OCT/OCTN, albeit at different relative amounts. 119 
cDNA synthesis was performed via reverse transcription using M-MLV reverse transcriptase 120 
(Invitrogen, UK) using generic random oligonucleotide (pdN6) primers and quantified  121 
 8 
spectrophotometrically at 260 and 280 nm by GeneQuant.  The cDNA was amplified as 122 
described elsewhere [26]. qPCR was performed by SYBR
®
 Green chemistry using a DNA 123 
Engine Opticon 2 Real-Time Cycler (BioRad, UK), previously described elsewhere [27]. The 124 
increase in fluorescence emission associated with DNA amplification was calculated 125 
throughout the run of 40 cycles and the cycle number at which fluorescence emission first 126 
reaches exponential phase was recorded.   127 
 128 
3. RESULTS 129 
3.1 Pulmonary transepithelial transport of [
3
H]-ipratropium and [
3
H]-L-carnitine  130 
We explored if OCT/OCTN-mediated transport was a significant feature in the transepithelial 131 
absorption (airway to pulmonary vascular space) of [
3
H]-ipratropium and [
3
H]-L-carnitine 132 
within an intact rat lung.  Over the 60 min IPRL experiment approximately 20% of the lung 133 
deposited dose of [
3
H]-ipratropium was absorbed to the recirculating vascular perfusate 134 
(Figure 1A, Table 2) with approximately 3% of [
3
H]-L-carnitine absorbed (Figure 1B, Table 135 
2). Pre-administration into the airways (20 min prior to that of radiolabelled substrate) of 125 136 
nmol of the respective unlabelled solute (either unlabelled ipratropium or L-carnitine) failed 137 
to significantly alter the extent or rate of absorption of the corresponding radiolabelled 138 
species. This despite the unlabeled solute dosed at a 3000-fold excess to that of the 139 
radiolabelled substrate.   Similarly, pre-administration of 125 nmol of MPP
+
 failed to alter 140 
[
3
H]-ipratroprium absorption profile and kinetics.  None of the above treatments resulted in 141 
perturbation of pulmonary barrier integrity or permeability as evidenced by the pulmonary 142 
absorption of the co-administered hydrophilic paracellular probe [
14
C] mannitol remaining 143 
unaffected (p>0.05) by any treatment (Table 2).   144 
 145 
 9 
3.2 OCT/OCTN-mediated accumulation of [
3
H]-ipratropium and [
3
H]-L-carnitine by 146 
primary rat pulmonary epithelial cells  147 
Real-time qPCR confirmed the presence of Slc22a1-Slc22a5 transcripts in both rat whole 148 
lung and in primary cultures of rat alveolar epithelial cells (Figure 1C), with the primary 149 
cultures relatively enriched, with respect to lung tissue, in Slc22a3 and Slc22a4.   As 150 
expected, we found the uptake of [
3
H]-ipratropium and [
3
H]-L-carnitine by the primary 151 
alveolar epithelial cells to display temperature dependency (data not shown). Furthermore, 152 
the accumulation of both solutes was significantly decreased (P < 0.05) by co-incubation with 153 
their respective unlabelled solute, or in the case of [
3
H]-ipratropium by the OCT inhibitor 154 
MPP
+ 
(Figure 1D); the effect of MPP
+
 upon L-carnitine uptake was not examined. 155 
3.3 OCT/OCTN-mediated accumulation of [
3
H]-ipratropium and [
3
H]-L-carnitine by 156 
human pulmonary cell lines 157 
We investigated the kinetics and transporter selectivity in the accumulation of [
3
H]-158 
ipratropium and [
3
H]-L-carnitine using human lung epithelial cell lines (A549, BEAS-2B, 159 
16HBE14o
-
) constitutively expressing OCT and OCTN transporter proteins. The 160 
accumulation of both [
3
H]-ipratropium and [
3
H]-L-carnitine (applied at 50 nM) was linear 161 
over a 60 min period (Supplementary Figure 1) with parallel experiments undertaken at 4 °C 162 
showing negligible cell-associated radioactivity (< 250 DPM/10
6
 cells at all timepoints; data 163 
not shown).  The cell lines demonstrated differing capacities to actively accumulate [
3
H]-164 
ipratropium  and [
3
H]-L-carnitine (Table 3) with all three cell types showing higher (P < 165 
0.05) levels of accumulation (per 10
6 
cells) for L-carnitine compared to ipratropium.  Of 166 
particular note was the considerable accumulation (P < 0.05) of [
3
H]-L-carnitine by BEAS-167 
2B cells, to the extent that 25% of the total applied L-carnitine radiolabel was cell-associated 168 
at 60 min  169 
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Using qPCR we evaluated solute accumulation by the various lung epithelial cell lines in the 170 
context of the absolute levels of SLC22A1-SLC22A5 mRNA transcripts in the cells.  Figure 171 
2A shows the results of the qPCR where the mass of cDNA (femtograms) for each respective 172 
mRNA transcript is expressed relative to a 2 ng mass of total cDNA.  Consistent with our 173 
observation of greater cellular accumulation of [
3
H]-L-carnitine in all three cell lines, the 174 
combined cDNA for SLC22A4 and SLC22A5 was more abundant in each of the three cell 175 
lines than the respective combined cDNA for SLC22A1, SLC22A2 and SLC22A3.  The 176 
BEAS-2B cell line showed the highest total SLC22A4 and SLC22A5 levels of all which was 177 
mirrored by a greater uptake displayed by BEAS-2B for L-carnitine.   178 
To further explore solute uptake and the interplay between constitutively expressed OCT and 179 
OCTN transporter proteins we examined the active accumulation of [
3
H]-ipratropium and 180 
[
3
H]-L-carnitine under challenge by various competitive inhibitors or co-factors (Figures 2B 181 
and 2C respectively). Not surprisingly, in all lung epithelial cell lines the accumulation of 182 
both radiolabelled ipratropium and L-carnitine was significantly (P < 0.05) decreased 183 
following co-incubation with their respective unlabelled solute. Challenge with unlabelled 184 
ipratropium resulted in a significant (P < 0.05) reduction of [
3
H]-L-carnitine accumulation in 185 
all three cell lines (Figure 2C). However, the effect of unlabelled L-carnitine upon [
3
H]-186 
ipratropium accumulation (Figure 2B)  resulted in a far more restricted response, with a 187 
reduction  (P < 0.05) in [
3
H]-ipratropium accumulation observed only in the BEAS-2B cells, 188 
and then only at a marginal level.  Co-incubation of  the highly selective OCT competitive 189 
inhibitor, MPP
+
, resulted in a significant (P < 0.05) inhibition of [
3
H]-ipratropium 190 
accumulation in all three cell lines with inhibitory effects most pronounced in A549 cells and 191 
with the least affected being the BEAS-2B cells (Figure 2B).  Notably MPP
+
 had no 192 
significant (P > 0.05) effect upon the accumulation of the OCTN substrate [
3
H]-L-carnitine 193 
(Figure 2C).   Challenge with TEA, a mixed OCT/OCTN inhibitor, resulted in decreases in 194 
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the accumulation of both [
3
H]-ipratropium (Figure 2B) and [
3
H]-L-carnitine (Figure 2C) in all 195 
three cell lines. OCTN1 and OCTN2 display Na
+
-dependent transport, and in all three lung 196 
epithelial cell lines the active accumulation of the OCTN substrate [
3
H]-L-carnitine was 197 
reduced by >90% (P < 0.05) in the absence of Na
+
 (Figure 2C).  In contrast, the accumulation 198 
of [
3
H]-ipratropium was significantly less dependent on Na
+
 (Figure 2B). Specifically, in the 199 
absence of Na
+
 no alteration in ipratropium accumulation was observed in A549 cells. In 200 
BEAS-2B and 16HBE14o
-
 cell lines, Na
+
 depletion had a greater effect on ipratropium 201 
uptake (25-40% inhibition; P < 0.05), that L-carnitine accumulation.   An MTT assay 202 
substantiated that none of the competitive inhibitors had any detrimental effect upon in vitro 203 
cell viability over the time course of experimentation (data not shown).   204 
 205 
4. Discussion 206 
The objective of this work was to examine the hypothesis that OCT and OCTN transporters 207 
play little or no role in the absorption of respective archetype substrates into the pulmonary 208 
circulation of a fully intact lung model. This set of experiments compliments a number of in-209 
vitro lung epithelial cell-based studies which infer that these transporters may fulfill a role in 210 
substrate access to sub-mucosal smooth muscle targets.   211 
Here we used an IPRL system to study transepithelial absorption from the airways, a  fully 212 
intact whole lung model retaining the relevant in-vivo biological architecture and the various  213 
sequential and parallel, e.g. paracellular, active/facilitative and passive transcellular routes 214 
that may contribute to various extents a substrate’s overall transepithelial  penetration. We 215 
have previously demonstrated that the IPRL can serve as a reliable and robust model that is 216 
capable of discriminating active transport pathways for substrate movement across lung 217 
epithelia.  For example, we have shown in the IPRL that P-glycoprotein (P-gp) drug efflux 218 
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reduces the pulmonary absorption of certain P-gp substrates [28], an efflux mechanism which 219 
can be inhibited in the IPRL by co-administration of the chemical inhibitors such as elacridar 220 
(GF-120918).  The IPRL displays similar airway perfusion characteristics to the fully intact 221 
in-vivo rat lung [29-31]. Indeed, in the IPRL the entire lung parenchyma from the secondary 222 
bronchi (second airway bifurcation) to the deep alveolar regions is perfused by the pulmonary 223 
circulation [30], as it is in vivo.  224 
The IPRL experiments (Figs 1A,B) demonstrate a non-saturable transport pathway for 225 
ipratropium and carnitine, as well as the absence of any demonstrable inhibition of 226 
ipratropium transport by MPP
+
.  This demonstrates that the OCT and OCTN transporters 227 
played no significant quantitative role in the overall transport of the substrates ipratropium 228 
and L-carnitine across the pulmonary barrier into the pulmonary circulation. This particular 229 
question has not previously been addressed. Although published studies have investigated the 230 
in-vitro cell uptake of OCT/OCTN substrates by pulmonary epithelial cells per se.  231 
In IRPL experiments radiolabelled [
3
H]-ipratropium and [
3
H]-L-carnitine were administered 232 
to the airways to achieve intraluminal concentrations at least 10-fold lower than their 233 
respective Km values (>1 µM) for OCT/OCTN [32]. These intra-luminal concentrations were 234 
determined to be close to those used in our parallel in-vitro uptake studies. Our calculations 235 
were based on a rat lung epithelial lining fluid (ELF) volume of 250 - 350 µL [21].  We 236 
found pre-administration of a 3000-fold excess of the respective unlabelled substrate did not 237 
alter the pulmonary absorption of either [
3
H]-ipratropium or [
3
H]-L-carnitine. Additionally, 238 
intra-luminal dosing of high concentration of the OCT inhibitor MPP
+
 concentrations 239 
(mimicking those used in in-vitro studies) did not influence [
3
H]-ipratropium absorption. 240 
These findings contrast with those of the in-vitro uptake studies which unequivocally showed 241 
saturable uptake processes for these substrates into lung epithelial cells. Nakanishi and co-242 
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workers reported that the tracheal accumulation of ipratropium in mice over a 90 second 243 
period was inhibited by both 0.2 and 1 mM carnitine and 0.1mM MPP
+ 
[14]. Backstrom et al 244 
[33] exploited a lung slice model to investigate the tissue binding of a number of inhaled drug 245 
molecules. For ipratropium they reported a bound drug partition coefficient of the cell i.e. the 246 
ratio of intracellular to extracellular unbound drug concentration of 7.1 and for its derivative, 247 
tiotropium, a value of 1.1. The authors concluded that OCT/OCTN transporter activity was 248 
responsible for this active accumulation of ipratropium but not for tiotropium, in spite of 249 
evidence from an analogous kidney slice model that tiotropium is an OCT substrate [19]. The 250 
tissue slice models used by Backstrom and others allow for a rapid and reliable investigation 251 
of bound:unbound drug levels in tissue homogenates. However, the model does not offer 252 
opportunity to investigate specific transport processes active at the luminal epithelial barrier 253 
such as airway to blood absorption. The epithelial and multiple sub-mucosal cell types 254 
distributed across the tissue slice are simultaneously exposed to equal concentrations of drug. 255 
This does not mimic the lung microenvironment in vivo following drug inhalation and 256 
therefore does not permit the differentiation of distinct tissue binding sites in the tissue slice. 257 
Of note, the extent of pulmonary absorption of ipratropium (bioavailability of 20% of lung 258 
dose absorbed) was significantly greater than the zwitterion, L-carnitine (bioavailability of 259 
3% of lung deposited dose absorbed) indicating a discrimination in the way the lung handles 260 
these charged molecules. Differences in tissue/protein binding at the epithelial surface within 261 
the lung, as dictated by physicochemical parameters such as logP, could serve to limit the 262 
fraction available for absorption into the pulmonary circulation. This whole lung absorption 263 
data nonetheless matches the low bioavailability of inhaled ipratropium in man after slow 264 
inhalation [34] and implies that the majority of the deposited dose remains either in the 265 
airway lumen or is localised to the lung submucosal tissue wherein lies the target smooth 266 
muscle cells.  267 
 14 
 268 
For the purposes of rigorous investigation we also undertook parallel in-vitro pulmonary 269 
epithelial cell uptake studies. Consistent with others we found that OCT and OCTN 270 
transporter proteins play a significant role in the in-vitro epithelial cell uptake of ipratropium 271 
and L-carnitine. We found that human lung epithelial cell lines displayed differing and 272 
opposing capacities for active uptake of ipratropium and L-carnitine. For example, BEAS-2B 273 
cells showing the lowest capacity for ipratropium accumulation but the highest for L-274 
carnitine, while A549 cells showed the reverse profile suggesting these solutes utilise to some 275 
extent distinct pathways for their active cellular accumulation. These results were in 276 
agreement with qPCR studies which showed BEAS-2B cells to have the highest potential for 277 
OCTN functionality with the combined  SLC22A4 and  SLC22A5 mRNA transcript levels 278 
approximately 8500-fold greater than the combined levels of the SLC22A1, SLC22A2 and 279 
SLC22A3 mRNA transcripts. Although our studies did not seek to directly correlate mRNA 280 
expression levels with transporter functionality in these cells lines it was noticeable that high 281 
levels of SLC22A4 and SLC22A5 mRNA in BEAS-2B matched the extensive accumulation of 282 
L-carnitine. We do not exclude however the contribution of another uptake transporter in L-283 
carnitine uptake. Similar observations have been made by Nakamura et al. [18], who reported 284 
high expression of OCTN mRNA and a lack of OCT(1-3) mRNA in BEAS-2B cells using 285 
semi-quantitative PCR. In contrast, Ingoglia et al [35] recently indicated that OCT3 and 286 
OCT1 could play a role in the uptake of MPP
+
 in BEAS-2B cells; a cell line which, in our 287 
hands, demonstrated negligible OCT3 expression by qPCR.  288 
In vitro studies using overexpression kidney cell systems have shown ipratropium to 289 
variously be a substrate for either OCT [19]  or OCTN transporters [18]. Consistent with 290 
these reports we show in the human respiratory cell lines, under conditions of constitutive 291 
expression and allowing for interplay between the transporter subfamilies, that ipratropium 292 
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serves as a transport substrate for both OCT and OCTN but with preference for the former.  293 
This is exemplified by Na
+
-free incubations, probing OCTN transporter function in 294 
particular, that revealed dramatic reductions in the uptake of the OCTN substrate L-carnitine 295 
in all the tested cell lines. Under the same conditions an appreciably smaller effect upon the 296 
uptake of ipratropium was observed, with uptake in the A549 cell line (displaying the highest 297 
relative OCT transcript levels) remaining unaffected by the absence of Na
+
.  Consistent with 298 
the above the OCT selective inhibitor, MPP
+
, had no effect on L-carnitine uptake but resulted 299 
in significant MPP
+
-mediated inhibition of ipratropium accumulation;  the less profound 300 
MPP
+
-mediated inhibition of ipratropium accumulation in BEAS-2B cells reflecting the 301 
considerably higher OCTN expression level in these cells that provides for a compensatory 302 
uptake. This latter point was reinforced by experiments involving co-incubation with excess 303 
unlabelled L-carnitine which reduced [
3
H]-ipratropium accumulation only in the ‘OCTN-304 
dominant’ BEAS-2B cells; a result that is in agreement with Nakamura et al. [18].  305 
Primary cultures of rat lung alveolar epithelial cells display the phenotypic and biochemical 306 
hallmarks of the in-vivo type-I pneumocyte, which presents the major constituent (95% 307 
surface area) of the lung epithelial barrier. In these cultures we found expression of 308 
OCT/OCTN family members and demonstrated in vitro functionality of these cells in the 309 
saturable accumulation of both [
3
H]-ipratropium and [
3
H]-L-carnitine; accumulation which 310 
could be inhibited by co-exposure to their respective unlabelled species, and in the case of 311 
ipratropium, by the OCT inhibitor, MPP
+
. Other studies in primary rat alveolar epithelial cells 312 
have reported mRNA for OCT1 and OCT3 [36]  by semi-quantitative PCR, while Miakotina 313 
et al. [37] observed expression of OCT1 protein in primary rat and mouse alveolar epithelial 314 
cells.   315 
 316 
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It is not currently understood why OCT substrates, such as ipratropium, demonstrate low 317 
extents of absorption into the pulmonary vasculature in spite of extensive in vitro evidence of 318 
transporter-facilitated transport into the mucosal epithelia. Unwalla et al [38] reported that the 319 
transepithelial transport of salbutamol is increased through relaxation of epithelia tight 320 
junctional complexes that results from the b2-receptor mediated rises in intracellular cAMP 321 
levels. This mechanism is not expected for ipratropium which acts via the M3 muscarinic 322 
receptor.  More likely is a complex and dynamic interplay between membrane transporters in 323 
the epithelial and submucosal lung tissue that serve in concert to limit the access of select 324 
solutes to the pulmonary vascular bed. 325 
 326 
5 Conclusions 327 
In conclusion we find no evidence for a role of OCT/OCTN in the absorption of L-carnitine 328 
or ipratropium across an intact lung epithelial barrier into the pulmonary circulation. This is 329 
despite evidence in cell lines, including primary cells from the same group of rats, that the 330 
transporters play a significant role in the uptake of the substrates in to the epithelial cells. It 331 
follows that the rate of delivery of such molecules from airspace to lung sub-mucosal tissue 332 
in the intact organ will predominately be driven by passive processes.  However, it is not 333 
possible to conclude that OCT and/or OCTN transporters lack influence upon localised 334 
submucosal pulmonary concentrations, and consequently upon the pharmacodynamic (PD) 335 
profiles for airway-administered cationic drugs.  Indeed, while OCT and/or OCTN 336 
transporters may lack significant impact upon the aggregate systemic levels of inhaled 337 
cationic drug, these transporters may still affect localised drug concentrations (e.g. recycling) 338 
in the pulmonary PD compartment(s) which is an issue that necessitates further PK/PD 339 
investigations in the future.  340 
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Table Legends: 451 
Table 1: Sequences of forward and reverse primers used in qPCR analysis of mRNA 452 
transcript levels in human pulmonary cell lines and rat cells/tissue. 453 
 454 
Table 2: Pharmacokinetic parameters, rate constant (k) and fraction absorbed (f) generated 455 
from modelling IPRL lung transport data of [
3
H]-ipratropium and [
3
H]-L-carnitine. The 456 
extent of absorption of the control permeability probe 
14
C-mannitol at 60 minutes is shown 457 
for comparison. Data are mean ± SD. The number of experimental replicates (n) is shown. 458 
 459 
Table 3: Percentage uptake of [
3
H]-ipratropium and [
3
H]-L-carnitine uptake in the three 460 
human cell lines A549, BEAS-2B and 16HBE14o
-
. 461 
 462 
 463 
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Figure Legends: 476 
Figure 1.  (1A) and (1B):  Cumulative airway to perfusate transport (expressed as % of total 477 
lung deposited dose) following instillation into the IPRL airways of 45 pmol [
3
H]-478 
ipratropium or [
3
H]-L-carnitine, respectively. Treatments included: (1A) airway co-479 
administration of unlabelled (cold) ipratropium (125 nmol) or MPP
+
 (125 nmol) or (1B) 480 
airway co-administration of unlabelled (cold) L-carnitine (125 nmol). Lines represent the 481 
predicted transport of each substrate based on mathematical modelling. (1C): Quantitative 482 
PCR results showing relative levels  of cDNA transcript corresponding to Slc22a1-5 483 
transporters in whole rat lung tissue, primary rat lung epithelial cells and rat liver (% signal 484 
expressed to 2 ng total cDNA). (1D):  Uptake (expressed as % of control) at 60 min (37°C) of 485 
50 nM [
3
H] ipratropium and 50 nM [
3
H] L-carnitine in primary culture rat epithelial cells 486 
when challenged by pre-incubation with either 500 µM unlabelled ipratropium, 100 µM 487 
unlabelled L-carnitine, MPP+ (500µM). * Represents statistical significance compared to 488 
respective control at P<0.05 by one-way ANOVA and Dunnett's post-hoc test. 489 
Figure 2. (2A): Real-time quantitative PCR results showing amounts of cDNA for OCT1, 490 
OCT2, OCT3, OCTN1 and OCTN2 mRNA transcripts in the three pulmonary cell lines 491 
expressed as femtograms / 2ng of total cDNA.  The insert shows the standard curves for gene 492 
transcripts. (2B) and (2C): % uptake of [
3
H]-ipratropium and [
3
H] L-carnitine in cell lines 493 
A549, BEAS-2B and 16HBE14o
-
 in the presence and absence of various inhibitors. Data 494 
shown are mean ± S.D., n=6-8.   * denotes statistical significance (P<0.05) in comparison to 495 
control (radiolabelled substrate only) using one-way ANOVA with Tukey’s post hoc test. 496 
Table 1. Sequences of forward and reverse primers used in qPCR analysis of mRNA 
transcript levels in human pulmonary cell lines and rat cells and tissue. 
 
Human  
Protein name Gene name  Primer Sequence  
OCT1 (SLC22A1) SLC22A1 Forward  5'- GCTCTACTACTGGTGTGTGTGCCGGA -'3 
SLC22A1 Reverse 5'- CTTGCCAGACCTCCCTCAGCCT -'3 
 
     OCT2 (SLC22A2) SLC22A2 Forward 5'- CGCATCGGACGCCGTTACCC -'3 
SLC22A2 Reverse 5'- CCAGCCAAGCACGCCGAAAAA -'3 
 
    OCT3 (SLC22A3) SLC22A3 Forward 5'- GGCACGCAGCCCGACCACTA -'3 
SLC22A3 Reverse 5'- CACTGCGCTTGTGAACCAAGCAAAC -'3 
 
    OCTN1 (SLC22A4) SLC22A4 Forward 5'- GCCTGTCCCCCGGGAACGTT -'3 
SLC22A4 Reverse 5'- AGATTCCACTCGGTCACGACGG -'3 
 
    OCTN2 (SLC22A5) SLC22A5 Forward 5'- GCCCTATGTAAGGCCAGCCGC -'3 
SLC22A5 Reverse 5'- CTCACACACCAGGTTCCACTCGG -'3 
Rat 
 OCT1 (SLC22A1) Slc22a1 Forward  5'- GCCTGGCTAAACTGGTGAGGGC -'3 
Slc22a1 Reverse 5'- CGGCCAAACCTGTCTGCAATGTA -'3 
 
   
 
OCT2 (SLC22A2) Slc22a2 Forward 5'- AGGGSCCATGTCGACCGTGGA -'3 
Slc22a2 Reverse 5'- TTCCGGCCAAACCTGTCCGCTAG -'3 
 
   
 
OCT3 (SLC22A3) Slc22a3 Forward 5'- AGCGGACAGATACGGCAGGCT -'3 
Slc22a3 Reverse 5'- CGGCAAAGGGAAGGCGTCGT -'3 
 
   
 
 OCTN1 (SLC22A4) Slc22a4 Forward 5'- CGCCGGACCCCTTTCTCCCAA -'3 
Slc22a4 Reverse 5'- CAACGATGCTCCGGGGTCCC -'3 
 
   
 
OCTN2 (SLC22A5) Slc22a5 Forward 5'- GGACGGCATGCGGGACTACG -‘3 
Slc22a5 Reverse 5'- GGATGAACCAGAGAGCCCCA -‘3 
 
  
Table 1
 
Table 2 Pharmacokinetic parameters, rate constant (k) and fraction absorbed (f) generated 
from modelling IPRL lung transport data of [
3
H]-ipratropium and [
3
H]-L-carnitine. The 
extent of absorption of the control permeability probe 
14
C-mannitol at 60 minutes is shown 
for comparison. Data are mean ± SD. The number of experimental replicates (n) is shown. 
 
 
Substrate/ 
Treatment 
 
n 
k                                                 
(min
-1
) 
f                                
(max =1) 
% [
14
C]-mannitol 
absorbed at 60 
min 
 
[
3
H] ipratropium  
 
6 0.042 ± 0.028 0.23 ± 0.095 28.5 ± 10.2 
[
3
H] ipratropium 
+ 125 nmol 
ipratropium 
 
6 0.043 ± 0.017 0.21 ± 0.070 26.6 ±11.5 
[
3
H] ipratropium 
+ 125 nmol MPP
+ 
 
4 0.047 ± 0.022 0.17 ± 0.027 22.8 ±2.3 
[
3
H] L-carnitine   
 
4 0.054 ± 0.020 0.030 ± 0.023 17.1 ±2.3 
[
3
H] L-carnitine +    
125 nmol L-
carnitine 
4 0.057 ± 0.030 0.032 ± 0.005 17.3 ± 6.0 
 
 
Table 2
 1 
Table 3 Percentage uptake of [
3
H]-ipratropium and [
3
H]-L-carnitine uptake in the three human cell lines 
A549, BEAS-2B and 16HBE14o
-
. 
 
 
 
 
 Cell Line A549 BEAS-2B 16HBE14o
-
 
% Ipratropium uptake / 10
6
 cells / hr 
 
1.6 ± 0.13 0.23 ± 0.03 0.60 ± 0.04 
% L-carnitine uptake  / 10
6
 cells /  hr 3.4 ± 0.13 25.3 ± 2.0 4.0   ± 0.3 
Table 3
Figure 1
Figure 2
